Molecular Dynamics Validation of Crizotinib Resistance to ALK Mutations (L1196M and G1269A) and Identification of Specific Inhibitors

• Published in: Journal of cellular biochemistry 2017-10, Vol.118 (10), p.3462-3471
• Main Authors: Nagasundaram, Nagarajan, Wilson Alphonse, Carlton Ranjith, Samuel Gnana, Prakash Vincent, Rajaretinam, Rajesh Kannan
• Format: Article
• Language: English
• Subjects: ALK; Amino Acid Substitution; Cancer; Carcinoma, Non-Small-Cell Lung - diet therapy; Carcinoma, Non-Small-Cell Lung - enzymology; Carcinoma, Non-Small-Cell Lung - genetics; Computer applications; Computer simulation; CRIZOTINIB; Drug development; Drug resistance; Drug Resistance, Neoplasm; Drugs; Humans; Inhibitors; LUNG CANCER; Lung Neoplasms - drug therapy; Lung Neoplasms - enzymology; Lung Neoplasms - genetics; Lymphoma; MOLECULAR DOCKING; Molecular dynamics; MOLECULAR DYNAMICS SIMULATION; Mutation; Mutation, Missense; Non-small cell lung carcinoma; Patients; PERSONALIZED MEDICINE; Protein Kinase Inhibitors - chemistry; Protein-tyrosine kinase; Pyrazoles - chemistry; Pyridines - chemistry; Receptor Protein-Tyrosine Kinases - antagonists & inhibitors; Receptor Protein-Tyrosine Kinases - chemistry; Receptor Protein-Tyrosine Kinases - genetics; Resistance factors; Targeted cancer therapy; Tyrosine
• ISSN: 0730-2312; 1097-4644
• DOI: 10.1002/jcb.26004

ABSTRACT Anaplastic lymphoma kinase (ALK) positive non‐small cell lung cancer (NSCLC) patients are mostly treated with ALK tyrosine kinase inhibitors (TKIs). Crizotinib is the first generation ALK inhibitor practiced as a primary chemo to combat cancer cells followed by second generation inhibitor ceritinib which are effective against crizotinib resistant ALK mutations. However, patients treated with these drugs invariably relapsed because of the development of new drug resistance mutations. In this study we explored the crizotinib resistance in the presence of ALK mutations L1196M and G1269A through molecular dynamics simulation studies. Further mutation specific inhibitors CID 71748211 and CID 71728095 were identified to potentially inhibit ALK with mutations L1196M and G1269A, respectively. This computational investigation in‐sighted the molecular factors involved in crizotinib resistance which enhanced in the identification of new ALK drugs that brings individualized medicine to treat ALK positive NSCLC patients with specific mutations. J. Cell. Biochem. 118: 3462–3471, 2017. © 2017 Wiley Periodicals, Inc. This computational investigation in‐sighted the molecular factors involved in crizotinib resistance which enhanced in the identification of new ALK drugs that bring individualized medicine to treat ALK positive NSCLC patients with specific mutations.